NO316054B1 - Anvendelse av forskolin eller ekstrakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet - Google Patents
Anvendelse av forskolin eller ekstrakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet Download PDFInfo
- Publication number
- NO316054B1 NO316054B1 NO19975155A NO975155A NO316054B1 NO 316054 B1 NO316054 B1 NO 316054B1 NO 19975155 A NO19975155 A NO 19975155A NO 975155 A NO975155 A NO 975155A NO 316054 B1 NO316054 B1 NO 316054B1
- Authority
- NO
- Norway
- Prior art keywords
- alcohol
- forskolin
- treatment
- manufacture
- extracts containing
- Prior art date
Links
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 title claims abstract description 28
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 14
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 title claims abstract description 14
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 title claims abstract description 4
- 201000007930 alcohol dependence Diseases 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- -1 17-p-acetoxy-8 Chemical compound 0.000 description 1
- NCVPMYNWDROSMF-UHFFFAOYSA-N 2-methoxyoxazinane Chemical compound CON1CCCCO1 NCVPMYNWDROSMF-UHFFFAOYSA-N 0.000 description 1
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 235000021508 Coleus Nutrition 0.000 description 1
- 244000061182 Coleus blumei Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BTZJQYVYGCCNHY-UHFFFAOYSA-N calcium;urea Chemical compound [Ca].NC(N)=O BTZJQYVYGCCNHY-UHFFFAOYSA-N 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI951023A IT1275436B (it) | 1995-05-19 | 1995-05-19 | Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza |
| PCT/EP1996/001952 WO1996036332A1 (fr) | 1995-05-19 | 1996-05-09 | Utilisation de forskoline ou d'extraits contenant cette substance dans la fabrication d'un medicament destine au traitement de l'alcoolisme |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975155D0 NO975155D0 (no) | 1997-11-10 |
| NO975155L NO975155L (no) | 1997-11-10 |
| NO316054B1 true NO316054B1 (no) | 2003-12-08 |
Family
ID=11371634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975155A NO316054B1 (no) | 1995-05-19 | 1997-11-10 | Anvendelse av forskolin eller ekstrakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5902823A (fr) |
| EP (1) | EP0825859B1 (fr) |
| JP (1) | JP3001641B2 (fr) |
| KR (1) | KR100423486B1 (fr) |
| CN (1) | CN1099286C (fr) |
| AT (1) | ATE215368T1 (fr) |
| AU (1) | AU697449B2 (fr) |
| CA (1) | CA2221592C (fr) |
| DE (1) | DE69620394T2 (fr) |
| DK (1) | DK0825859T3 (fr) |
| ES (1) | ES2175099T3 (fr) |
| HK (1) | HK1005651A1 (fr) |
| HU (1) | HU223474B1 (fr) |
| IT (1) | IT1275436B (fr) |
| NO (1) | NO316054B1 (fr) |
| PT (1) | PT825859E (fr) |
| RU (1) | RU2183455C2 (fr) |
| WO (1) | WO1996036332A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU740356B2 (en) | 1997-07-30 | 2001-11-01 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
| EP1645272A3 (fr) * | 1998-05-12 | 2008-11-05 | The Endowment For Research In Human Biology, Inc. | Dérivés de daidzin pour le traitement de l'alcoolisme |
| US20060122261A1 (en) * | 2003-11-20 | 2006-06-08 | Muhammed Majeed | [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] |
| WO2008042795A2 (fr) * | 2006-09-29 | 2008-04-10 | The Board Of Trustees Of The University Of Illinois | Activateurs de l'histone acétyltransférase et inhibiteurs d'histone déacétylase dans le traitement de l'alcoolisme |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4120975A (en) * | 1976-08-26 | 1978-10-17 | Fisons Limited | Method of psychiatric conditions |
| US4782082A (en) * | 1982-12-27 | 1988-11-01 | Schering Corporation | Method for treating allergic reactions with Forskolin |
| IL89530A0 (en) * | 1989-03-08 | 1989-09-10 | Jeffrey J Feigenbaum | Compositions containing forskolin |
| US5366990A (en) * | 1991-11-14 | 1994-11-22 | Reid Larry D | Method for treating alcohol abuse and alcoholism |
-
1995
- 1995-05-19 IT ITMI951023A patent/IT1275436B/it active IP Right Grant
-
1996
- 1996-05-09 ES ES96919731T patent/ES2175099T3/es not_active Expired - Lifetime
- 1996-05-09 AT AT96919731T patent/ATE215368T1/de not_active IP Right Cessation
- 1996-05-09 US US08/952,472 patent/US5902823A/en not_active Expired - Fee Related
- 1996-05-09 EP EP96919731A patent/EP0825859B1/fr not_active Expired - Lifetime
- 1996-05-09 HU HU9801236A patent/HU223474B1/hu not_active IP Right Cessation
- 1996-05-09 KR KR1019970708221A patent/KR100423486B1/ko not_active IP Right Cessation
- 1996-05-09 CA CA002221592A patent/CA2221592C/fr not_active Expired - Fee Related
- 1996-05-09 RU RU97120756/14A patent/RU2183455C2/ru active
- 1996-05-09 CN CN96194036A patent/CN1099286C/zh not_active Expired - Fee Related
- 1996-05-09 DE DE69620394T patent/DE69620394T2/de not_active Expired - Fee Related
- 1996-05-09 DK DK96919731T patent/DK0825859T3/da active
- 1996-05-09 AU AU58163/96A patent/AU697449B2/en not_active Ceased
- 1996-05-09 WO PCT/EP1996/001952 patent/WO1996036332A1/fr active Search and Examination
- 1996-05-09 PT PT96919731T patent/PT825859E/pt unknown
- 1996-05-09 JP JP8534525A patent/JP3001641B2/ja not_active Expired - Fee Related
-
1997
- 1997-11-10 NO NO19975155A patent/NO316054B1/no not_active IP Right Cessation
-
1998
- 1998-06-03 HK HK98104794A patent/HK1005651A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2183455C2 (ru) | 2002-06-20 |
| ITMI951023A0 (it) | 1995-05-19 |
| NO975155D0 (no) | 1997-11-10 |
| CN1184422A (zh) | 1998-06-10 |
| HU223474B1 (hu) | 2004-07-28 |
| ES2175099T3 (es) | 2002-11-16 |
| HK1005651A1 (en) | 1999-01-22 |
| NO975155L (no) | 1997-11-10 |
| CA2221592C (fr) | 2002-07-09 |
| DK0825859T3 (da) | 2002-07-29 |
| AU5816396A (en) | 1996-11-29 |
| CN1099286C (zh) | 2003-01-22 |
| HUP9801236A2 (hu) | 2000-06-28 |
| ATE215368T1 (de) | 2002-04-15 |
| AU697449B2 (en) | 1998-10-08 |
| CA2221592A1 (fr) | 1996-11-21 |
| EP0825859A1 (fr) | 1998-03-04 |
| EP0825859B1 (fr) | 2002-04-03 |
| ITMI951023A1 (it) | 1996-11-19 |
| WO1996036332A1 (fr) | 1996-11-21 |
| DE69620394D1 (de) | 2002-05-08 |
| JP3001641B2 (ja) | 2000-01-24 |
| JPH11500738A (ja) | 1999-01-19 |
| HUP9801236A3 (en) | 2001-09-28 |
| DE69620394T2 (de) | 2002-10-02 |
| US5902823A (en) | 1999-05-11 |
| IT1275436B (it) | 1997-08-07 |
| KR100423486B1 (ko) | 2004-06-05 |
| PT825859E (pt) | 2002-08-30 |
| KR19990014876A (ko) | 1999-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2219502C (fr) | Procede et formulations servant a moduler la reaction sexuelle chez l'homme ou la femme | |
| CN105250285B (zh) | 预防和治疗成瘾的组合物和方法 | |
| US6197827B1 (en) | Nicotine addiction treatment | |
| US4777173A (en) | Method for treatment of alcohol abuse | |
| US20030215531A1 (en) | Compositions and methods of use for extracts of Rutaceae plants | |
| US6469044B1 (en) | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies | |
| NO316054B1 (no) | Anvendelse av forskolin eller ekstrakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet | |
| Wayner et al. | Effects of acute and chronic administration of caffeine on schedule dependent and schedule induced behavior | |
| EP0824356B1 (fr) | Compositions pharmaceutiques pour le traitement de l'alcoolisme | |
| US11026989B2 (en) | Composition for treating erectile dysfunction by Orchis anatolica extract | |
| EP1347778B1 (fr) | Chimiotherapie de comportement | |
| WO2022048176A1 (fr) | Utilisation de rabdosia serra, et composition de rabdosia serra | |
| TWI313607B (fr) | ||
| CN110179889A (zh) | 一种用于戒断海洛因毒瘾的中药组合物及其制备方法 | |
| Campaigne | " Speaker of the Year" Address, 1983-84: Drugs and the Mind |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |